<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12888815</article-id><article-id pub-id-type="pmc">2394366</article-id><article-id pub-id-type="pii">6601155</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Hypersensitivity reactions related to oxaliplatin (OHP)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brandi</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pantaleo</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Galli</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Falcone</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Antonuzzo</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mordenti</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Marco</surname><given-names>M C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Biasco</surname><given-names>G</given-names></name></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Institute of Haematology and Medical Oncology &#x02018;L.&#x00026; A. Seragnoli&#x02019;, University of Bologna, Policlinico Sant'Orsola, Via Massarenti 9, 40138 Bologna, Italy</aff><aff id="aff2"><label>2</label><sup>2</sup>Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno Viale Alfieri 36, 58128 Livorno, Italy</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:gbrandi@med.unibo.it">gbrandi@med.unibo.it</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>07</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>04</day><month>08</month><year>2003</year></pub-date><volume>89</volume><issue>3</issue><fpage>477</fpage><lpage>481</lpage><history><date date-type="received"><day>08</day><month>07</month><year>2002</year></date><date date-type="rev-recd"><day>22</day><month>04</month><year>2003</year></date><date date-type="accepted"><day>25</day><month>05</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>Hypersensitivity reaction</kwd><kwd>platinum compound</kwd><kwd>colorectal cancer</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front><body><p>Oxaliplatin (OHP) is the most recent platinum compound entering the clinical practice. It is an alkylating agent on DNA and forms DACH-platinum DNA adducts more hydrophobic than those formed by cisplatin (CDDP) and carboplatin (CBDCA). It is effective in advanced colorectal cancer both as a first-line therapy and in 5-fluorouracil (5-FU) refractory patients (<xref ref-type="other" rid="bib2">Bertheault-Cvitkovic <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib8">De Gramont <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib1">Andre' <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib24">Maindrault-Goebel <italic>et al</italic>, 1999</xref>).</p><p>OHP is less nephro-ototoxic than CDDP and less mielotoxic than CBDCA (<xref ref-type="other" rid="bib27">Misset 1998</xref>). The most characteristic and dose-limiting toxicity of OHP is sensory neuropathy, which is dose cumulative and schedule related. It is clinically characterised by a transient acute cold-related dysaesthesias, sometimes pain-associated, or with cramps and functional failure, although it is generally reversible (<xref ref-type="other" rid="bib3">Caussanel <italic>et al</italic>, 1990</xref>, <xref ref-type="other" rid="bib27">Misset, 1998</xref>). Hypersensitivity reactions to oxaliplatin have been described only sporadically.</p><p>For other platinum compounds, this kind of reaction is well known (<xref ref-type="other" rid="bib4">Cleare <italic>et al</italic>, 1976</xref>; <xref ref-type="other" rid="bib40">Wiesenfeld <italic>et al</italic>, 1979</xref>; <xref ref-type="other" rid="bib32">Planner <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib29">Morgan <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib39">Weideman <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib35">Shleback <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib25">Markman <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib31">&#x000d6;zg&#x000fc;roglu <italic>et al</italic>, 1999</xref>). On data sheets of OHP, these clinical features are not stressed. In fact, only the main severe form of hypersensitivity, that is to say anaphylaxis, is reported in 0.5&#x00025; of patients treated. This reaction is clinically characterised by laryngospasm and wheezing and immunologically linked to the release of histamine and other vaso-active substances.</p><p>As a result of the increasing use of OHP in colorectal cancer, we have found frequent hypersensitivity reactions. In this study, we report the epidemiological and clinical features of these reactions, as well as their management.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>From February 1999 to February 2002 at the Institute of Haematology and Medical Oncology &#x02018;L. and A. Seragnoli&#x02019; of Bologna and at the Medical Oncology Division of Livorno, 124 outpatients with advanced colorectal cancer were treated with OHP-based therapies. Eighty-four out of 124 patients (67.7&#x00025;) received OHP as a first-line treatment. Fifty-five patients (44.3&#x00025;) were treated with a FOLFOX-4 regimen (<xref ref-type="other" rid="bib1">Andre' <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib6">De Gramont <italic>et al</italic>, 2000</xref>), 34 patients (27.4&#x00025;) with FOLFOX-3 regimen (<xref ref-type="other" rid="bib7">De Gramont <italic>et al</italic>, 1999</xref>), 30 patients (24.1&#x00025;) with the association of OHP&#x0002f;CPT-11&#x0002f;c.i.5-FU&#x0002f;FA regimen (<xref ref-type="other" rid="bib11">Falcone <italic>et al</italic>, 2002</xref>), three patients (2.4&#x00025;) with OHP alone (<xref ref-type="other" rid="bib9">Diaz-Rubio <italic>et al</italic>, 1998</xref>) and two patients (1.6&#x00025;) with OHP&#x0002f;Raltitrexed regimen (<xref ref-type="other" rid="bib34">Seitz <italic>et al</italic>, 1999</xref>). All patients received a standard antiemetic treatment with ondansetron 8&#x02009;mg by a i.v. administration before chemotherapy. We did not use dexamethasone in this population.</p><p>Major sites of metastases were the liver, lungs and peritoneum. Among these patients, 17 out of 124 (13.7&#x00025;) reported a hypersensitivity reaction attributable to OHP. There were eight males and nine female patients, with a mean age of 60.3 years (range 37&#x02013;76). In 11 out of 17 patients with hypersensitivity reaction, OHP was administered in first-line chemotherapy.</p></sec><sec><title>RESULTS</title><p>Results are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patients with hypersensitivity reactions</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="center"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Case</bold></th><th align="left" valign="top" charoff="50"><bold>Sites of metastases</bold></th><th align="left" valign="top" charoff="50"><bold>Chemotherapy regimen</bold></th><th align="left" valign="top" char="." charoff="50"><bold>Infusion number at reaction</bold></th><th align="left" valign="top" char="." charoff="50"><bold>Total dose of OHP (mg)</bold></th><th align="left" valign="top" charoff="50"><bold>Clinical features of reaction</bold></th><th align="left" valign="top" charoff="50"><bold>Length of reaction (min)</bold></th><th align="left" valign="top" charoff="50"><bold>Treatment of reaction</bold></th><th align="left" valign="top" charoff="50"><bold>Re-exposure to OHP with premedication and outcome</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">Lung</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">382</td><td align="left" valign="top" charoff="50">Bronchospasm</td><td align="center" valign="top" charoff="50">7 days</td><td align="left" valign="top" charoff="50">Hospitalisation&#x0002f;high dose of steroid</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Laryngospasm</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">14</td><td align="char" valign="top" char="." charoff="50">2100</td><td align="left" valign="top" charoff="50">Bronchospasm</td><td align="center" valign="top" charoff="50">60</td><td align="left" valign="top" charoff="50">Oxygen</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Eriythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">Oxaliplatin</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">2070</td><td align="left" valign="top" charoff="50">Bronchospasm</td><td align="center" valign="top" charoff="50">50</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hypotension</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-3</td><td align="char" valign="top" char="." charoff="50">17</td><td align="char" valign="top" char="." charoff="50">2271</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">5&#x02013;10</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">Yes, with reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Lung</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand, face oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Erythema, itching</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Psychomotor agitation</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">Oxalipatin</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">360</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">120</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Laryngospasm</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">Irinotecan</td><td align="char" valign="top" char="." charoff="50">11</td><td align="char" valign="top" char="." charoff="50">1620</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">15&#x02013;20</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Oxaliplatin</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Eye oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Fluorouracil</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Face erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Folinic acid</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Itching</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Sweating</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-3</td><td align="char" valign="top" char="." charoff="50">17</td><td align="char" valign="top" char="." charoff="50">2720</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">15&#x02013;20</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">Yes, with reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Lung</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Sweating</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Lachrymation</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">8</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">900</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">30</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Itching</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Mouth oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">1120</td><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="center" valign="top" charoff="50">60</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Lung</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand, face erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">10</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">1360</td><td align="left" valign="top" charoff="50">Erythema,</td><td align="center" valign="top" charoff="50">15&#x02013;20</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Tachycardia</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Precordial pain</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Pruritus</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">11</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">630</td><td align="left" valign="top" charoff="50">Hand oedema, Hand genital itching</td><td align="center" valign="top" charoff="50">20</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">Yes, without reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand, face erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">12</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">940</td><td align="left" valign="top" charoff="50">Hand face erythema</td><td align="center" valign="top" charoff="50">20&#x02013;30</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand oedema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hand itching</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">Irinotecan</td><td align="char" valign="top" char="." charoff="50">14</td><td align="char" valign="top" char="." charoff="50">2600</td><td align="left" valign="top" charoff="50">Itching</td><td align="center" valign="top" charoff="50">15&#x02013;20</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">Yes, with reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">Oxaliplatin</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Sweating</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Anthistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Fluorouracil</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Lachrymation</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Folinic acid</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Face oedema,</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Face erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">7</td><td align="char" valign="top" char="." charoff="50">1040</td><td align="left" valign="top" charoff="50">Face, chest erythema</td><td align="center" valign="top" charoff="50">120</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">Yes, with reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Itching</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">15</td><td align="left" valign="top" charoff="50">Liver</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">13</td><td align="char" valign="top" char="." charoff="50">1705</td><td align="left" valign="top" charoff="50">Face, chest erythema</td><td align="center" valign="top" charoff="50">50</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Shiver without fever</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Antihistaminic</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Tremor</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">16</td><td align="left" valign="top" charoff="50">Diaphragm</td><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">8</td><td align="char" valign="top" char="." charoff="50">1080</td><td align="left" valign="top" charoff="50">Arms, chest erythema</td><td align="center" valign="top" charoff="50">50</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">Yes, with reaction</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">With pomphoid reaction</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">17</td><td align="left" valign="top" charoff="50">Peritoneum</td><td align="left" valign="top" charoff="50">FOLFOX-3</td><td align="char" valign="top" char="." charoff="50">9</td><td align="char" valign="top" char="." charoff="50">1377</td><td align="left" valign="top" charoff="50">Sweating</td><td align="center" valign="top" charoff="50">15&#x02013;20</td><td align="left" valign="top" charoff="50">Steroids</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Erythema</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Hypotension</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Nausea</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table></table-wrap>. The reaction occurs after a mean&#x000b1;s.e.&#x0003d;9.4&#x000b1;1.07 infusions of chemotherapy (range 2&#x02013;17). Only two patients experienced early hypersensitivity at the second and third infusion, respectively.</p><p>On average, there were 217.7&#x000b1;32.5 days (mean&#x000b1;s.e.) (range 74&#x02013;575) between the first exposure to OHP and the reaction.</p><p>Eight out of 124 (6.5&#x00025;) patients reported only erythema and itching of the palms and flushing of the face and hands after the beginning of OHP infusion. Nine out of 124 (7.3&#x00025;) patients developed a more severe reaction with dyspnoea, wheezing, laryngospasm, psico-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Only two patients experienced the symptoms at the end of the infusion, while the others developed the reaction between 10 to 15&#x02009;min from the start of OHP infusion. All patients showing hypersensitivity were treated with steroids, many of them in association with antihistaminic drugs. The symptoms disappeared within half an hour to 2&#x02009;h after stopping the OHP infusion and the beginning of the antiallergic therapy. One patient required hospitalisation for dyspnoea that disappeared in a few days.</p><p>Once the reaction had disappeared, nine patients continued the scheduled drug infusions, in particular 5-fluorouracile (5-FU) and Folinic acid, without any additional problem.</p><p>The percentage of reaction is different according to the chemotherapy regimens employed: 66.6&#x00025; for OHP alone, 18.1&#x00025; for FOLFOX-4 regimen, 8.8&#x00025; for FOLFOX-3 regimen and 6.6&#x00025; for OHP&#x0002f;CPT-11&#x0002f;c.i.5-FU&#x0002f;FA regimen (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Number of reactions according to the regimen</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Chemotherapy regimen</bold></th><th align="left" valign="top" char="." charoff="50"><bold>No. of patients</bold></th><th align="left" valign="top" char="." charoff="50"><bold>No. of reactions</bold></th><th align="left" valign="top" char="." charoff="50"><bold>&#x00025; reaction according to the regimen</bold></th><th align="left" valign="top" char="." charoff="50"><bold>Mean no. of infusions at the reaction onset</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">FOLFOX-4</td><td align="char" valign="top" char="." charoff="50">55</td><td align="char" valign="top" char="." charoff="50">10</td><td align="char" valign="top" char="." charoff="50">18.1</td><td align="char" valign="top" char="." charoff="50">8.1</td></tr><tr><td align="left" valign="top" charoff="50">FOLFOX-3</td><td align="char" valign="top" char="." charoff="50">34</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">8.8</td><td align="char" valign="top" char="." charoff="50">14.3</td></tr><tr><td align="left" valign="top" charoff="50">Irinotecan Oxaliplatin Fuorouracil Folinic acid</td><td align="char" valign="top" char="." charoff="50">30</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">6.6</td><td align="char" valign="top" char="." charoff="50">12.5</td></tr><tr><td align="left" valign="top" charoff="50">Oxaliplatin</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">66.6</td><td align="char" valign="top" char="." charoff="50">6</td></tr></tbody></table></table-wrap>).</p><p>Three patients developed the reaction to the first chemotherapy treatment after a long period of rest. The total administered doses of OHP in patients developing the reaction are reported in <xref rid="tbl1" ref-type="table">Table 1</xref>. The cumulative dose of OHP was 1428&#x02009;mg&#x000b1;176.7 (mean&#x000b1;s.e.) (range 360&#x02013;2720&#x02009;mg).</p><p>Six out of 17 patients with hypersensitivity reactions were successively re-exposed to OHP chemotherapy after premedication with steroids and antihistaminic drugs. Five of these six patients developed the same symptoms again, while one patient had no further reaction.</p></sec><sec><title>DISCUSSION</title><p>Hypersensitivity reactions to platinum compounds are a well-known phenomena (<xref ref-type="other" rid="bib41">Weiss, 1992</xref>). In the 1950s, literature reported the capacity of platinum salts to induce bronchial asthma among platinum-refinery workers (<xref ref-type="other" rid="bib14">Hunter <italic>et al</italic>, 1945</xref>). It is not surprising that after the introduction of platinum compounds into chemotherapy, their association with type I hypersensitivity reactions was confirmed (<xref ref-type="other" rid="bib4">Cleare <italic>et al</italic>, 1976</xref>). These reactions were first described for CDDP with a 5&#x02013;20&#x00025; incidence (<xref ref-type="other" rid="bib40">Wiesenfeld <italic>et al</italic>, 1979</xref>; <xref ref-type="other" rid="bib35">Shleback <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib31">&#x000d6;zg&#x000fc;roglu <italic>et al</italic>, 1999</xref>), and evidence regarding similar reactions for CBDCA are also available (<xref ref-type="other" rid="bib32">Planner <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib29">Morgan <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib39">Weideman <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib25">Markman <italic>et al</italic>, 1999</xref>).</p><p>This kind of toxicity has been sporadically reported in clinical trials focusing on the effectiveness of OHP in chemotherapy or described as case reports (<xref ref-type="other" rid="bib22">Machover <italic>et al</italic>, 1996</xref>; Diaz Rubio <italic>et al</italic>, 1998; <xref ref-type="other" rid="bib38">Tournigand <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib15">Larzilliere <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib26">Medioni <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib6">De Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib10">Dold <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib28">Monnet <italic>et al</italic>, 2002</xref>).</p><p>Our results support the assumption that this side effect should not be underestimated. More than 13&#x00025; of OHP-treated patients developed hypersensitivity reaction. This phenomenon is not well known, probably because OHP entered clinical practice only a few years ago. Moreover, according to our experience, the reactions generally develop after about 9&#x02013;10 infusions. The relationship between the hypersensitivity reaction and OHP is supported by the following evidence. First, the symptoms developed a few minutes after starting the OPH infusion; secondly, the patients re-exposed to successive OHP administration developed a similar reaction; thirdly, two patients developed a reaction after monochemotherapy OHP infusion; finally, in patients treated with OHP&#x0002f;CPT-11&#x0002f;c.i. 5-FU&#x0002f;FA regimen, the reaction could be confused with a cholinergic syndrome due to CPT-11, but the responsibility of CPT-11 can be excluded since the re-exposure to CPT-11&#x0002f;c.i. 5-FU&#x0002f;FA without OHP was not able to provoke the hypersensitivity reaction.</p><p>The pathophysiology of hypersensitivity reactions is not clear, but the finding that almost all patients developed the reaction after multiple infusions of treatment suggests the need to be sensitised during previous cycles. Symptoms usually develop early after the start of the infusion and have been ascribed to a type I hypersensitivity Ig-E-mediated reaction (<xref ref-type="other" rid="bib36">Stahl <italic>et al</italic>, 2001</xref>).</p><p>A different hypothesis suggests that platinum salts could induce an oligo or polyclonal T-cells expansion. These compounds can act as a superantigen on the peripheral blood mononuclear cells, thus releasing a large amount of proinflammatory cytokines (IL-6, TNF<italic>&#x003b1;</italic>, <italic>&#x003b3;</italic> interferon) (<xref ref-type="other" rid="bib33">Santini <italic>et al</italic>, 2001</xref>). The other possible mechanism consists in binding the platinum salts to different peptides of major histocompatibility complex (MHC).</p><p>In fact, HLA phenotype is a significant determinant of occupational sensitisation to inhaled hapten of complex platinum salts and the strength of this association varies according to the intensity of exposure (<xref ref-type="other" rid="bib30">Newman Taylor <italic>et al</italic>, 1999</xref>).</p><p>Furthermore, the relationship between hypersensitivity reactions and HLA-haplotype has been described for other drugs (<xref ref-type="other" rid="bib13">Hetherington <italic>et al</italic>, 2002</xref>). Additional factors are deemed to be necessary to the immune system for developing the reaction after several infusions.</p><p>Apart from hypersensitivity-related dyspnoea and wheezing, the lung may also be the target of a particular toxicity. A patient treated with OHP-5FU therapy developed severe dyspnoea. A bronchus alveolar lavage (BAL) and a lung biopsy diagnosed a diffuse alveolar damage that disappeared with steroid therapy (<xref ref-type="other" rid="bib37">Trisolini <italic>et al</italic>, 2001</xref>).</p><p>In our experience, when a hypersensitivity reaction occurred, the infusion of OHP was immediately stopped and replaced by a saline infusion, an intravenous antihistaminic drug and a low-dose corticosteroids administration. In the case of more severe reactions (dyspnoea, sweating, bronchospasm, laryngospasm), we immediately administered a high dose of steroid. The steroid dose ranged between 100 and 1000&#x02009;mg of hydrocortisone. After the reaction disappeared, the OHP infusion was not restarted and the decision to administer the other scheduled drugs was taken evaluating the clinical status of the patient after the reaction, the risk of additional toxicity and the clinical utility of the chemotherapy. In this way, about two-thirds of patients (11 patients) continued the infusion of other planned antiblastic drugs without any additional clinical problems.</p><p>In order to avoid further hypersensitivity problems in successive cycles, one can presumably explore a maximum prophylactic immunological blockage with a high dose of steroids and antihistaminic drugs for several days before the infusion of OHP, but the real benefit is uncertain because five out of six patients treated with steroids and&#x0002f;or antihistaminic drugs immediately before re-exposure developed the same intensity of reaction.</p><p>Documented data suggest that OHP as a continuous 6-h infusion seems to decrease the risk of hypersensitivity reactions. Only one out of 100 (1&#x00025;) patients treated with OHP as a 6-h infusion added to chronomodulated 5-FU&#x02013;FA as a first-line treatment of advanced colorectal cancer developed hypersensitivity-like reactions (<xref ref-type="other" rid="bib12">Giacchetti <italic>et al</italic>, 2000</xref>). When OHP is infused in a chronomodulate setting (as a 12-h infusion) or flat infusion for 5 days, these hypersensitivity reactions do not occur. In particular, 151 patients submitted to 1087 constant rate continuous infusion courses of OHP, and 491 patients submitted to 3106 chronomodulate OHP courses did not experience any hypersensitivity reactions (<xref ref-type="other" rid="bib3">Caussanel <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib17">Levi <italic>et al</italic>, 1992</xref>, <xref ref-type="other" rid="bib18">1993</xref>, <xref ref-type="other" rid="bib21">1994b</xref>, <xref ref-type="other" rid="bib20">1997</xref>, <xref ref-type="other" rid="bib19">1999</xref>; <xref ref-type="other" rid="bib2">Bertheault-Cvitkovic <italic>et al</italic>, 1996</xref>).</p><p>Therefore, the incapacity of these schedules to produce hypersensitivity might be due to a long time infusion rather than to failure of activation of the immune system (which presents a circadian rhythm) in a chronomodulate setting (<xref ref-type="other" rid="bib16">Levi <italic>et al</italic>, 1994a</xref>).</p><p>Interestingly, five patients who developed hypersensitivity reactions to 2-h OHP infusion, when re-exposed to 6-h OHP infusion, did not show any symptoms (<xref ref-type="other" rid="bib23">Maindrault-Goebel <italic>et al</italic>, 2001</xref>). The mechanism is still unclear, although it is supposed that the maximum concentration reached by the drug is lower in a longer time of infusion. Theoretically this situation might occur with increased hydration, but no data are available. In the adjuvant setting, the number of allergic reactions is different from the advanced disease. In fact only 2&#x00025; of the allergic, not already specified, reactions have been reported (<xref ref-type="other" rid="bib5">De Gramont <italic>et al</italic>, 2002</xref>). The reason for this important difference is unclear.</p><p>It could be possible that the tumour releases factors able to make the immune system more sensitive, but no data are available.</p><p>In our study, neither the cumulative dose of OHP nor the lapse of time between the first exposition and the reaction are able to predict the hypersensitivity reaction. In our experience, the severity of clinical symptoms is variable and we cannot identify the patients at risk of developing the reaction or the factors indicating the patients where the reaction could be more severe. Particular attention is necessary when the lung is the target of reaction, because the re-exposure to OHP generally affects the same site with higher intensity. Special care is mandatory in patients receiving OHP for a long time and&#x0002f;or re-exposing to OHP after a pause.</p><p>In conclusion, a late hypersensitivity reaction seems a limiting toxicity of OHP administered in 2&#x02009;h, and in patients previously affected it is advisable to avoid readministration of OHP with the same short schedule.</p><p>Literature data suggest that long-term OHP infusions are able to prevent the hypersensitivity reaction. The use of steroids does not seem useful in preventing hypersensitivity in patients having experienced previous reactions. On the contrary, long-term infusions, without dose decreasing, may prevent this reaction in patients previously affected, but a larger number of cases are required to provide definite responses on this matter.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andre'</surname><given-names>T</given-names></name><name><surname>Bensmaine</surname><given-names>MA</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Lucas</surname><given-names>V</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Beerblock</surname><given-names>K</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Dupont-Andre</surname><given-names>G</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name></person-group><article-title>Multicentric phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>3560</fpage><lpage>3568</lpage><!--PubMed citation query: 'J Clin Oncol||17|3560||bib1|'--><pub-id pub-id-type="pmid">10550155</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertheault-Cvitkovic</surname><given-names>F</given-names></name><name><surname>Jami</surname><given-names>A</given-names></name><name><surname>Ithzaki</surname><given-names>M</given-names></name><name><surname>Depr&#x000e8;s Brummer</surname><given-names>P</given-names></name><name><surname>Brienza</surname><given-names>R</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name></person-group><article-title>Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2950</fpage><lpage>2958</lpage><!--PubMed citation query: 'J Clin Oncol||14|2950||bib2|'--><pub-id pub-id-type="pmid">8918492</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caussanel</surname><given-names>JP</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Itazhaki</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Milano</surname><given-names>G</given-names></name><name><surname>Hecquet</surname><given-names>B</given-names></name><name><surname>Math&#x000e8;</surname><given-names>Get</given-names></name></person-group><article-title>Phase II trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate</article-title><source>J Natl Cancer Inst</source><year>1990</year><volume>82</volume><fpage>1046</fpage><lpage>1050</lpage><!--PubMed citation query: 'J Natl Cancer Inst||82|1046||bib3|'--><pub-id pub-id-type="pmid">2348469</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cleare</surname><given-names>MJ</given-names></name><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Jacob</surname><given-names>B</given-names></name><name><surname>Pepys</surname><given-names>B</given-names></name></person-group><article-title>Immediate (type I) allergic responses to platinum compounds</article-title><source>Clin Allergy</source><year>1976</year><volume>6</volume><fpage>183</fpage><lpage>195</lpage><!--PubMed citation query: 'Clin Allergy||6|183||bib4|'--><pub-id pub-id-type="pmid">1277442</pub-id></citation></ref><ref id="bib5"><citation citation-type="other"><person-group person-group-type="author"><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Tarbenero</surname><given-names>J</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>Topham</surname><given-names>C</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Clingan</surname><given-names>P</given-names></name><name><surname>Dvidson</surname><given-names>N</given-names></name><name><surname>Mounedji-Boudiaf</surname><given-names>L</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>T</given-names></name></person-group><article-title>Oxaliplatin&#x0002f;5-FU&#x0002f;LV in adjuvant colon cancer: safety results of the international randomized MOSAIC Trial</article-title><year>2002</year>Abstract 525, ASCO 2002</citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seynour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Corte-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>De Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><!--PubMed citation query: 'J Clin Oncol||18|2938||bib6|'--><pub-id pub-id-type="pmid">10944126</pub-id></citation></ref><ref id="bib7"><citation citation-type="other"><person-group person-group-type="author"><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Gilles-Amar</surname><given-names>V</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of oxaliplatin dose-intensity with the bimonthly 48&#x02009;h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in pretreated metastatic colorectal cancer</article-title><year>1999</year>Proceedings ASCO 1999</citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Vignoud</surname><given-names>J</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andr</surname><given-names>T</given-names></name><name><surname>Varette</surname><given-names>C</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Moreau</surname><given-names>S</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer</article-title><source>Eur J Cancer</source><year>1997</year><volume>33</volume><fpage>214</fpage><lpage>219</lpage><!--PubMed citation query: 'Eur J Cancer||33|214||bib8|'--><pub-id pub-id-type="pmid">9135491</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Sastre</surname><given-names>J</given-names></name><name><surname>Zaniboni</surname><given-names>A</given-names></name><name><surname>La bianca</surname><given-names>R</given-names></name><name><surname>Cort&#x000e8;s-Funes</surname><given-names>H</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Benavides</surname><given-names>M</given-names></name><name><surname>Dallavalle</surname><given-names>G</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name></person-group><article-title>Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study</article-title><source>Ann Oncol</source><year>1998</year><volume>9</volume><fpage>105</fpage><lpage>108</lpage><!--PubMed citation query: 'Ann Oncol||9|105||bib9|'--><pub-id pub-id-type="pmid">9541691</pub-id></citation></ref><ref id="bib10"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Dold</surname><given-names>F</given-names></name><name><surname>Hoey</surname><given-names>D</given-names></name><name><surname>Carbery</surname><given-names>M</given-names></name><name><surname>Musket</surname><given-names>A</given-names></name><name><surname>Friedberg</surname><given-names>V</given-names></name><name><surname>Mitchell</surname><given-names>E</given-names></name></person-group><article-title>Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin</article-title><year>2002</year>Abstract 1478, ASCO 2002</citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Allegrini</surname><given-names>G</given-names></name><name><surname>Dansei</surname><given-names>R</given-names></name><name><surname>Pfanner</surname><given-names>E</given-names></name><name><surname>Brunetti</surname><given-names>IM</given-names></name><name><surname>Di Paolo</surname><given-names>A</given-names></name><name><surname>Cupini</surname><given-names>S</given-names></name><name><surname>Del Tacca</surname><given-names>M</given-names></name><name><surname>Conte</surname><given-names>P</given-names></name></person-group><article-title>Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4006</fpage><lpage>4014</lpage><!--PubMed citation query: 'J Clin Oncol||20|4006||bib11|'--><pub-id pub-id-type="pmid">12351598</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>Perpoint</surname><given-names>B</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Faggiuolo</surname><given-names>R</given-names></name><name><surname>Focan</surname><given-names>C</given-names></name><name><surname>Chollet</surname><given-names>P</given-names></name><name><surname>Llory</surname><given-names>JF</given-names></name><name><surname>Letornou</surname><given-names>Y</given-names></name><name><surname>Coudert</surname><given-names>B</given-names></name><name><surname>Bertheault-Cvitkovic</surname><given-names>F</given-names></name><name><surname>Larregain-Fournier</surname><given-names>D</given-names></name><name><surname>Le Rol</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name></person-group><article-title>Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil&#x02013;leucovrin as first line treatment of metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>136</fpage><lpage>147</lpage><!--PubMed citation query: 'J Clin Oncol||18|136||bib12|'--><pub-id pub-id-type="pmid">10623704</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hetherington</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>AR</given-names></name><name><surname>Mosteller</surname><given-names>M</given-names></name><name><surname>Shortino</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>KL</given-names></name><name><surname>Spreen</surname><given-names>W</given-names></name><name><surname>Lai</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>K</given-names></name><name><surname>Handley</surname><given-names>A</given-names></name><name><surname>Dow</surname><given-names>DJ</given-names></name><name><surname>Fling</surname><given-names>ME</given-names></name><name><surname>Stocum</surname><given-names>M</given-names></name><name><surname>Bowan</surname><given-names>C</given-names></name><name><surname>Thurmond</surname><given-names>LM</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name></person-group><article-title>Genetic variations in HLA-B region and hypersensitivity reactions to abacavir</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1121</fpage><lpage>1122</lpage><!--PubMed citation query: 'Lancet||359|1121||bib13|'--><pub-id pub-id-type="pmid">11943262</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>D</given-names></name><name><surname>Milton</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>KMA</given-names></name></person-group><article-title>Asthma caused by complex salts of platinum</article-title><source>Br J Ind Med</source><year>1945</year><volume>2</volume><fpage>92</fpage><lpage>98</lpage><!--PubMed citation query: 'Br J Ind Med||2|92||bib14|'--></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larzilliere</surname><given-names>I</given-names></name><name><surname>Brandissou</surname><given-names>S</given-names></name><name><surname>Breton</surname><given-names>P</given-names></name><name><surname>Lingoungou</surname><given-names>A</given-names></name><name><surname>Gargot</surname><given-names>D</given-names></name><name><surname>Ramain</surname><given-names>JP</given-names></name><name><surname>Harnois</surname><given-names>C</given-names></name></person-group><article-title>Anaphylactic reaction to oxaliplatin: a case-report</article-title><source>AJG</source><year>1999</year><volume>94</volume><fpage>3387</fpage><lpage>3388</lpage><!--PubMed citation query: 'AJG||94|3387||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Bourin</surname><given-names>P</given-names></name><name><surname>Depr&#x000e8;-Brummer</surname><given-names>P</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name></person-group><article-title>Chronobiology of the immune system. Implication for the delivery of therapeutic agents</article-title><source>Clin Immunother</source><year>1994a</year><volume>2</volume><fpage>53</fpage><lpage>64</lpage><!--PubMed citation query: 'Clin Immunother||2|53||bib16|'--></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Metzeger</surname><given-names>G</given-names></name><name><surname>Itzakhi</surname><given-names>M</given-names></name><name><surname>Caussanel</surname><given-names>JP</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Lecouturier</surname><given-names>S</given-names></name><name><surname>Descorp-Decler&#x000e8;</surname><given-names>A</given-names></name><name><surname>Jasmin</surname><given-names>C</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Reinberg</surname><given-names>A</given-names></name></person-group><article-title>A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump</article-title><source>Cancer</source><year>1992</year><volume>69</volume><fpage>893</fpage><lpage>900</lpage><!--PubMed citation query: 'Cancer||69|893||bib17|'--><pub-id pub-id-type="pmid">1735081</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Perpoint</surname><given-names>B</given-names></name><name><surname>Garufi</surname><given-names>C</given-names></name><name><surname>Focan</surname><given-names>C</given-names></name><name><surname>Chollet</surname><given-names>P</given-names></name><name><surname>Depres-Brummer</surname><given-names>P</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Iacobelli</surname><given-names>S</given-names></name><name><surname>Kurstilnger</surname><given-names>F</given-names></name><name><surname>Gastiaburu</surname><given-names>J</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continous venous infusion at circadian rhythm modulated rate</article-title><source>Eur J Cancer</source><year>1993</year><volume>29</volume><fpage>1280</fpage><lpage>1284</lpage><!--PubMed citation query: 'Eur J Cancer||29|1280||bib18|'--></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Dogliotti</surname><given-names>L</given-names></name><name><surname>Perpoint</surname><given-names>B</given-names></name><name><surname>Rotsrski</surname><given-names>M</given-names></name><name><surname>Letourneau</surname><given-names>Y</given-names></name><name><surname>Llory</surname><given-names>JF</given-names></name><name><surname>Chollet</surname><given-names>P</given-names></name><name><surname>Le Rol</surname><given-names>A</given-names></name><name><surname>Focan</surname><given-names>C</given-names></name></person-group><article-title>A multicentric evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovrin as initial treatment of patients with metastatic colorectal cancer</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>2532</fpage><lpage>2540</lpage><!--PubMed citation query: 'Cancer||85|2532||bib19|'--><pub-id pub-id-type="pmid">10375099</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Randomised multicentric trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>681</fpage><lpage>686</lpage><!--PubMed citation query: 'Lancet||350|681||bib20|'--><pub-id pub-id-type="pmid">9291901</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Zidani</surname><given-names>R</given-names></name><name><surname>Vannetzel</surname><given-names>JM</given-names></name><name><surname>Perpoint</surname><given-names>B</given-names></name><name><surname>Focan</surname><given-names>C</given-names></name><name><surname>Faggiuolo</surname><given-names>R</given-names></name><name><surname>Chollet</surname><given-names>P</given-names></name><name><surname>Garufi</surname><given-names>C</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Dogliotti</surname><given-names>L</given-names></name><name><surname>Iacobelli</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Kunstilnger</surname><given-names>F</given-names></name><name><surname>Gastaburu</surname><given-names>J</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Jasmin</surname><given-names>C</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Chronomodulated <italic>versus</italic> fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial</article-title><source>J Natl Caner Inst</source><year>1994b</year><volume>86</volume><fpage>1608</fpage><lpage>1617</lpage><!--PubMed citation query: 'J Natl Caner Inst||86|1608||bib21|'--></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machover</surname><given-names>D</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Schilf</surname><given-names>A</given-names></name><name><surname>Gastiburu</surname><given-names>JJ</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>G</given-names></name><name><surname>N'Daw</surname><given-names>D</given-names></name><name><surname>Vignoud</surname><given-names>J</given-names></name><name><surname>Abad</surname><given-names>A</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Sstre</surname><given-names>J</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name></person-group><article-title>Two consecutive phase II studies of oxaliplatin (l-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><fpage>95</fpage><lpage>98</lpage><!--PubMed citation query: 'Ann Oncol||7|95||bib22|'--></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andr&#x000e8;</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Atru</surname><given-names>P</given-names></name><name><surname>Gilles</surname><given-names>V</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name><name><surname>for the Oncology Multidisciplanary Research Group</surname><given-names>(GERCOR</given-names></name></person-group><article-title>High-dose intensity oxaliplatin added to the simplified bimonthly leucovrin and 5-fluorouracil regimen as second line therapy for metastatic colorectal cancer (FOLFOX 7)</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>1000</fpage><lpage>1005</lpage><!--PubMed citation query: 'Eur J Cancer||37|1000||bib23|'--><pub-id pub-id-type="pmid">11334725</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andr&#x000e8;</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Lotz</surname><given-names>JP</given-names></name><name><surname>Molitor</surname><given-names>JL</given-names></name><name><surname>Garcia</surname><given-names>ML</given-names></name><name><surname>Giller-Amar</surname><given-names>V</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name></person-group><article-title>Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimens as second-line therapy for metastatic colorectal cancer (FOLFOX-6)</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>1338</fpage><lpage>1342</lpage><!--PubMed citation query: 'Eur J Cancer||35|1338||bib24|'--><pub-id pub-id-type="pmid">10658524</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Markman</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>A</given-names></name><name><surname>Webster</surname><given-names>K</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><name><surname>Peterson</surname><given-names>G</given-names></name><name><surname>Kulp</surname><given-names>B</given-names></name><name><surname>Belison</surname><given-names>J</given-names></name></person-group><article-title>Clinical features of hypersensitivity reactions to carboplatin</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1141</fpage><lpage>1145</lpage><!--PubMed citation query: 'J Clin Oncol||17|1141||bib25|'--><pub-id pub-id-type="pmid">10561172</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medioni</surname><given-names>J</given-names></name><name><surname>Coulon</surname><given-names>MA</given-names></name><name><surname>Morere</surname><given-names>JF</given-names></name><name><surname>Hennebelle</surname><given-names>F</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S</given-names></name><name><surname>Breau</surname><given-names>JL</given-names></name></person-group><article-title>Anaphylaxis after oxaliplatin</article-title><source>Ann Oncol</source><year>1999</year><volume>10</volume><fpage>610</fpage><!--PubMed citation query: 'Ann Oncol||10|610||bib26|'--><pub-id pub-id-type="pmid">10416017</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Oxaliplatin in practice</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><supplement>Suppl 4</supplement><fpage>4</fpage><lpage>7</lpage><!--PubMed citation query: 'Br J Cancer||77|4||bib27|'--><pub-id pub-id-type="pmid">9647612</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monnet</surname><given-names>I</given-names></name><name><surname>De Cremoux</surname><given-names>H</given-names></name><name><surname>Soulie'</surname><given-names>P</given-names></name><name><surname>Saltiel-Voisin</surname><given-names>S</given-names></name><name><surname>Bekradda</surname><given-names>M</given-names></name><name><surname>Saltiel</surname><given-names>JC</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Yataghene</surname><given-names>Y</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name></person-group><article-title>Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicentric phase II study</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>103</fpage><lpage>107</lpage><!--PubMed citation query: 'Ann Oncol||13|103||bib28|'--><pub-id pub-id-type="pmid">11863089</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>JS</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Mason</surname><given-names>MD</given-names></name></person-group><article-title>Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma</article-title><source>Eur J Cancer</source><year>1994</year><volume>30A</volume><supplement>8</supplement><fpage>1205</fpage><lpage>1206</lpage><!--PubMed citation query: 'Eur J Cancer||30A|1205||bib29|'--><pub-id pub-id-type="pmid">7654458</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman Taylor</surname><given-names>AJ</given-names></name><name><surname>Cullinan</surname><given-names>P</given-names></name><name><surname>Lympany</surname><given-names>PA</given-names></name><name><surname>Harris</surname><given-names>JM</given-names></name><name><surname>Dowdeswell</surname><given-names>RJ</given-names></name><name><surname>DuBois</surname><given-names>RM</given-names></name></person-group><article-title>Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts</article-title><source>Am J Resp Crit Care Med</source><year>1999</year><volume>160</volume><fpage>435</fpage><lpage>438</lpage><!--PubMed citation query: 'Am J Resp Crit Care Med||160|435||bib30|'--></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zg&#x000fc;roglu</surname><given-names>M</given-names></name><name><surname>Demir</surname><given-names>G</given-names></name><name><surname>Demirelli</surname><given-names>F</given-names></name><name><surname>Mandel</surname><given-names>NM</given-names></name></person-group><article-title>Anaphylaxis from intraperitoneal infusion of cisplatin</article-title><source>Am J Clin Oncol</source><year>1999</year><volume>22</volume><fpage>172</fpage><lpage>173</lpage><!--PubMed citation query: 'Am J Clin Oncol||22|172||bib31|'--><pub-id pub-id-type="pmid">10199453</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Planner</surname><given-names>RS</given-names></name><name><surname>Weerasiri</surname><given-names>T</given-names></name><name><surname>Timmins</surname><given-names>D</given-names></name><name><surname>Grant</surname><given-names>P</given-names></name></person-group><article-title>Hypersensitivity reaction to carboplatin</article-title><source>J Natl Cancer</source><year>1991</year><volume>83</volume><supplement>23</supplement><fpage>1763</fpage><lpage>1764</lpage><!--PubMed citation query: 'J Natl Cancer||83|1763||bib32|'--></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Tonini</surname><given-names>G</given-names></name><name><surname>Salerno</surname><given-names>A</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Patti</surname><given-names>G</given-names></name><name><surname>Dicuonzo</surname><given-names>G</given-names></name><name><surname>La Bianca</surname><given-names>R</given-names></name></person-group><article-title>Idiosyncratic reaction after oxaliplatin infusion</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>132</fpage><lpage>133</lpage><!--PubMed citation query: 'Ann Oncol||12|132||bib33|'--><pub-id pub-id-type="pmid">11249043</pub-id></citation></ref><ref id="bib34"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name></person-group><article-title>Tomudex (raltitrexed) plus oxaliplatin as fisrt line chemotherapy in metastatic colorectal cancer (MCRC): a promising combination</article-title><year>1999</year>Abstract 257, ASCO 1999</citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shleback</surname><given-names>AA</given-names></name><name><surname>Clark</surname><given-names>PI</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name></person-group><article-title>Hypersensitivity and cross-reactivity to cisplatin and analogues</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>35</volume><fpage>349</fpage><lpage>351</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||35|349||bib35|'--><pub-id pub-id-type="pmid">7828281</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>K&#x000f6;ster</surname><given-names>W</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name></person-group><article-title>Reaction after oxaliplatin&#x02013;prevention with corticosteroids</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>874</fpage><!--PubMed citation query: 'Ann Oncol||12|874||bib36|'--><pub-id pub-id-type="pmid">11484969</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trisolini</surname><given-names>R</given-names></name><name><surname>Lazzari Agli</surname><given-names>L</given-names></name><name><surname>Tassinari</surname><given-names>D</given-names></name><name><surname>Rondelli</surname><given-names>D</given-names></name><name><surname>Cancelleri</surname><given-names>A</given-names></name><name><surname>Patelli</surname><given-names>M</given-names></name><name><surname>Falcone</surname><given-names>F</given-names></name><name><surname>Poletti</surname><given-names>V</given-names></name></person-group><article-title>Acute lung injury associated with 5-fluorouracil and oxaliplatin combined chemotherapy</article-title><source>Eur Respir J</source><year>2001</year><volume>18</volume><fpage>243</fpage><lpage>245</lpage><!--PubMed citation query: 'Eur Respir J||18|243||bib37|'--><pub-id pub-id-type="pmid">11510798</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Maindrault-Goebel</surname></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>De Gramont</surname><given-names>A</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Severe anaphylactic reactions of oxaliplatin</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>1297</fpage><lpage>1298</lpage><!--PubMed citation query: 'Eur J Cancer||34|1297||bib38|'--><pub-id pub-id-type="pmid">9849497</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weideman</surname><given-names>B</given-names></name><name><surname>M&#x000fc;lleneisen</surname><given-names>N</given-names></name><name><surname>Bojko</surname><given-names>P</given-names></name><name><surname>Niederle</surname><given-names>N</given-names></name></person-group><article-title>Hypersensitivity reactions to carboplatin</article-title><source>Cancer</source><year>1994</year><volume>73</volume><fpage>2218</fpage><lpage>2222</lpage><!--PubMed citation query: 'Cancer||73|2218||bib39|'--><pub-id pub-id-type="pmid">8156529</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiesenfeld</surname><given-names>M</given-names></name><name><surname>Reiders</surname><given-names>E</given-names></name><name><surname>Corder</surname><given-names>M</given-names></name><name><surname>Yoo</surname><given-names>IJ</given-names></name><name><surname>Lovett</surname><given-names>J</given-names></name></person-group><article-title>Successful re-treatment with <italic>cis</italic>-dichlorodiammineplatinum (II) after apparent allergic reactions</article-title><source>Cancer Treat Rep</source><year>1979</year><volume>63</volume><fpage>219</fpage><lpage>221</lpage><!--PubMed citation query: 'Cancer Treat Rep||63|219||bib40|'--><pub-id pub-id-type="pmid">87272</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>RB</given-names></name></person-group><article-title>Hypersensitivity reactions</article-title><source>Semin Oncol</source><year>1992</year><volume>19</volume><fpage>458</fpage><lpage>477</lpage><!--PubMed citation query: 'Semin Oncol||19|458||bib41|'--><pub-id pub-id-type="pmid">1384149</pub-id></citation></ref></ref-list></back></article>


